Breath-hold BOLD fMRI without CO
BOLD
CBF
CBV
CVR
breath-hold
fMRI
Journal
NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515
Informations de publication
Date de publication:
07 Dec 2023
07 Dec 2023
Historique:
received:
22
02
2023
revised:
30
10
2023
accepted:
06
12
2023
pubmed:
10
12
2023
medline:
10
12
2023
entrez:
9
12
2023
Statut:
aheadofprint
Résumé
BOLD fMRI signal has been used in conjunction with vasodilatory stimulation as a marker of cerebrovascular reactivity (CVR): the relative change in cerebral blood flow (CBF) arising from a unit change in the vasodilatory stimulus. Using numerical simulations, we demonstrate that the variability in the relative BOLD signal change induced by vasodilation is strongly influenced by the variability in deoxyhemoglobin-containing cerebral blood volume (CBV), as this source of variability is likely to be more prominent than that of CVR. It may, therefore, be more appropriate to describe the relative BOLD signal change induced by an isometabolic vasodilation as a proxy of deoxygenated CBV (CBV
Identifiants
pubmed: 38070840
pii: S1053-8119(23)00642-0
doi: 10.1016/j.neuroimage.2023.120492
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120492Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Emma Biondetti reports financial support was provided by European Union, Italian Ministry of Education, University and Research. Richard G. Wise reports financial support was provided by European Union, Wellcome Trust. Michael Germuska reports financial support was provided by Wellcome Trust, UK Engineering and Physical Sciences Research Council. Kevin Murphy reports financial support was provided by Wellcome Trust. Valentina Tomassini reports financial support was provided by Multiple Sclerosis Society UK. Valentina Tomassini reports a relationship with Biogen, Almirall, Lundbeck, Roche, Novartis, Viatris, Alexion that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.